Palisade Bio develops oral drug candidates for inflammatory bowel disease, led by PALI-2108 for ulcerative colitis and Crohn's disease. PALI reports earnings on Mon, Nov 9, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 13 | HC Wainwright & Co. | Reiterated | Buy | |
| Oct 9 | Raymond James | Initiated | Buy | |
| Jul 23 | Oppenheimer | Initiated | Buy | |
| Apr 9 | Wolfe Research | Initiated | Buy |
Seasonality
How PALI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in PALI in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PALI is in one of them and how their past PALI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PALI in an article yet. Here's the latest on the wider market.
About Palisade Bio
Palisade Bio is a biopharmaceutical company based in Carlsbad, California, that is developing oral medicines for inflammatory bowel disease. Its lead candidate, PALI-2108, is a pill taken once a day that stays inactive until it reaches the lower intestine, where gut bacteria convert it into an active drug at sites of inflammation. The company is testing the candidate in people with ulcerative colitis and Crohn's disease. Its candidates are still in clinical testing and are not yet on the market.
- Headquarters
- Carlsbad, CA